JP2023550428A5 - - Google Patents
Info
- Publication number
- JP2023550428A5 JP2023550428A5 JP2023530225A JP2023530225A JP2023550428A5 JP 2023550428 A5 JP2023550428 A5 JP 2023550428A5 JP 2023530225 A JP2023530225 A JP 2023530225A JP 2023530225 A JP2023530225 A JP 2023530225A JP 2023550428 A5 JP2023550428 A5 JP 2023550428A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- crystalline material
- crystal
- peaks
- angles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116042P | 2020-11-19 | 2020-11-19 | |
| US63/116,042 | 2020-11-19 | ||
| PCT/US2021/072510 WO2022109598A1 (en) | 2020-11-19 | 2021-11-19 | Integrin inhibitor and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550428A JP2023550428A (ja) | 2023-12-01 |
| JP2023550428A5 true JP2023550428A5 (enExample) | 2024-11-26 |
Family
ID=81709878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530225A Pending JP2023550428A (ja) | 2020-11-19 | 2021-11-19 | インテグリン阻害剤およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12018025B2 (enExample) |
| EP (1) | EP4247472A4 (enExample) |
| JP (1) | JP2023550428A (enExample) |
| KR (1) | KR20230121761A (enExample) |
| CN (1) | CN116710169A (enExample) |
| AU (1) | AU2021381516A1 (enExample) |
| CA (1) | CA3173755A1 (enExample) |
| CL (1) | CL2023001418A1 (enExample) |
| CO (1) | CO2023006522A2 (enExample) |
| CR (1) | CR20230262A (enExample) |
| CU (1) | CU20230026A7 (enExample) |
| DO (1) | DOP2023000101A (enExample) |
| EC (1) | ECSP23045278A (enExample) |
| IL (1) | IL302651A (enExample) |
| JO (1) | JOP20230102A1 (enExample) |
| MX (1) | MX2023005889A (enExample) |
| PE (1) | PE20240114A1 (enExample) |
| TW (1) | TW202235417A (enExample) |
| WO (1) | WO2022109598A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE50554E1 (en) | 2016-12-23 | 2025-08-26 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| US11419869B2 (en) | 2019-04-08 | 2022-08-23 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| CN120091811A (zh) * | 2022-07-09 | 2025-06-03 | 普利安特治疗公司 | 整合素抑制剂及其与其它药剂组合的用途 |
| WO2024155965A2 (en) * | 2023-01-21 | 2024-07-25 | Pliant Therapeutics, Inc. | Biomarkers for use in integrin inhibitor therapy |
| WO2025072206A1 (en) * | 2023-09-25 | 2025-04-03 | Pliant Therapeutics, Inc. | Integrin inhibitors for treatment of primary sclerosing cholangitis |
| TW202535400A (zh) | 2023-12-14 | 2025-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| WO2025217571A1 (en) * | 2024-04-12 | 2025-10-16 | Pliant Therapeutics, Inc. | Fixed dose combinations of integrin inhibitor with ppar agonists |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013184572A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| USRE50554E1 (en) | 2016-12-23 | 2025-08-26 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| SG11201907820SA (en) | 2017-02-28 | 2019-09-27 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| LT3761980T (lt) | 2018-03-07 | 2024-03-12 | Pliant Therapeutics, Inc. | Aminorūgščių junginiai ir jų panaudojimo būdai |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020016704A1 (ja) * | 2018-07-20 | 2020-01-23 | 株式会社半導体エネルギー研究所 | 撮像パネル、撮像装置 |
| CA3109534A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting .alpha.v .beta.6 integrin |
| EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| ES3027421T3 (en) | 2018-08-29 | 2025-06-13 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3903316A1 (en) * | 2018-12-28 | 2021-11-03 | LunaPBC | Community data aggregation, completion, correction, and use |
| EP3923857B8 (en) * | 2019-02-15 | 2024-04-17 | Clean Bite, LLC | Oral hygiene appliance |
| US11419869B2 (en) * | 2019-04-08 | 2022-08-23 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| EP4058481A1 (en) | 2019-11-15 | 2022-09-21 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
| CN115989235A (zh) | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| TWI838626B (zh) * | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| WO2022087224A1 (en) * | 2020-10-21 | 2022-04-28 | Cohbar, Inc. | Method of treating fibrosis with a combination therapy |
| CA3173787A1 (en) | 2021-04-30 | 2022-11-03 | Scott Turner | Expanded dosage regimens for integrin inhibitors |
| US20240350494A1 (en) | 2021-09-03 | 2024-10-24 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| EP4416147A1 (en) | 2021-10-14 | 2024-08-21 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
-
2021
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en not_active Abandoned
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en not_active Ceased
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 EP EP21895890.8A patent/EP4247472A4/en not_active Withdrawn
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko not_active Withdrawn
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
-
2023
- 2023-05-08 JO JOJO/P/2023/0102A patent/JOP20230102A1/ar unknown
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
-
2024
- 2024-03-27 US US18/619,017 patent/US20240391914A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2968180B1 (en) | Heterocyclic compounds and their uses | |
| TW201010992A (en) | Pharmaceutical composition | |
| EP1492568A1 (en) | Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor | |
| CN105120844A (zh) | 杂环化合物和其用途 | |
| JP2004537597A5 (enExample) | ||
| JPWO2019151405A1 (ja) | 錠剤及びその製造方法 | |
| JP2023550428A (ja) | インテグリン阻害剤およびその使用 | |
| JP2009534373A5 (enExample) | ||
| OA12810A (en) | Tolterodine 12 salts. | |
| JP2025506098A5 (enExample) | ||
| CN104592195A (zh) | 一种苯甲酸阿格列汀的制备方法 | |
| JPH07598B2 (ja) | 光学的に純粋な化合物およびその製造方法 | |
| PT1651641E (pt) | Derivados de nicotinamida úteis como inibidores de pde4. | |
| JP2014518281A (ja) | 電位依存性ナトリウムチャネル遮断薬 | |
| JP2025516683A5 (enExample) | ||
| JP7788128B2 (ja) | 呼吸器疾患の治療のための化合物 | |
| JP2004530695A (ja) | ガボキサドールの顆粒状調合物 | |
| JP2021529805A5 (enExample) | ||
| JP2024506942A5 (enExample) | ||
| CN104721828A (zh) | 一种改善晶体药物稳定性的药物组合物及其制备方法 | |
| WO2025107982A1 (zh) | 一种吡非尼酮衍生物及其制备方法与应用 | |
| CN115443264A (zh) | 新型化合物[2-(二甲基氨基)-2-苯基丁基]-3,4,5-三甲氧基苯甲酸酯4-甲基-2h-色烯-2-酮-7-基硫酸盐及其用途 | |
| HU228035B1 (en) | Pharmaceutical compositions using terfenadine metabolites in combination with leukotriene inhibitors | |
| JP2009519985A5 (enExample) | ||
| CN102391107A (zh) | 没食子酸喹诺酮类药物盐及其制剂的制备方法 |